Please use this identifier to cite or link to this item:
|Title:||Optimizing streptomyces sp. MD102 for heterologous expression of the cannabinoid biosynthetic pathway||Authors:||Chea, Rachel Andrea Yuen Fong||Keywords:||Science::Biological sciences||Issue Date:||2020||Publisher:||Nanyang Technological University||Source:||Chea, R. A. Y. F. (2020). Optimizing streptomyces sp. MD102 for heterologous expression of the cannabinoid biosynthetic pathway. Master's thesis, Nanyang Technological University, Singapore.||Abstract:||Natural products synthesized from various plants or microorganisms have contributed significantly to drug development and discovery. In many cases, these secondary metabolites are generated at low levels in native hosts and the extraction of these compounds from some of these hosts may be time-consuming and costly. In recent years, there has been a growing interest in the development of suitable heterologous hosts to circumvent this problem. Amongst the various microorganisms studied, the Streptomyces genus has been shown to be ideal for heterologous expression. Our research team has recently isolated over 400 Actinobacteria strains around Singapore, one of which, MD102, is a fast-growing strain that shows potential of becoming a functional proprietary heterologous host. In this study, we endeavored to optimize MD102 and explore its capacity as a chassis for the production of cannabinoids, a group of secondary metabolites innately produced by Cannabis sativa. The pharmaceutical properties of cannabinoids have been widely accepted for many years. However, research efforts have been impeded by several constraints, such as legal restrictions and the extensive time needed for compound extraction. Following the optimization of MD102, we proposed the use of this strain for the production of cannabinoid compounds. To optimize MD102, we first utilized the CRISPR-Cas9 genome editing tool to delete competing endogenous biosynthetic pathways and to obtain a strain with a clean metabolic profile. Concurrently, we evaluated the effectiveness of the base editor system in the silencing of some of these gene clusters. Further optimization was performed by the incorporation of genes involved in the mevalonate and cannabinoid biosynthetic pathways. While our results suggest that the necessary components were successfully integrated in the chromosome of MD102, the final product was not detected in the high-performance liquid chromatography (HPLC) profile of the cell extract, indicating the need for further troubleshooting and optimization.||URI:||https://hdl.handle.net/10356/145184||DOI:||10.32657/10356/145184||Rights:||This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).||Fulltext Permission:||embargo_20221214||Fulltext Availability:||With Fulltext|
|Appears in Collections:||SBS Theses|
Files in This Item:
|Rachel Chea_G1802106K_MSc Thesis.pdf|
|This work is pending publication and patent application. This request is approved with reference no.:EM_2020_12_Chea Rachel Andrea Yuen Fong.||4.19 MB||Adobe PDF||Under embargo until Dec 14, 2022|
Updated on Jul 28, 2021
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.